Pgy1/PGY2 Program
Investigational Drugs and Research

About the PGY1 Pharmacy/PGY2 Investigational Drugs and Research Residency Program



PGY1 pharmacy residency programs build on Doctor of Pharmacy (PharmD) education and outcomes to contribute to the development of clinical pharmacists responsible for medication related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy residency training.

PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.

Residents completing the PGY1 Pharmacy/PGY2 Investigational Drugs and Research residency program at The Ohio State University Wexner Medical Center (OSUWMC) will gain specialized knowledge and skills to operate as an effective and expert practitioner in research pharmacy.  Residents will have the opportunity to interact with world-renowned researchers in both oncology and non-oncology areas throughout the medical center.  By the end of their PGY-2 program, the resident will have the training required to seek a specialized research pharmacist position in a variety of settings including, but not limited to, hospitals, academia, and industry.

Residents completing the PGY1 Pharmacy/PGY2 Investigational Drugs and Research Residency are eligible to receive a PGY1 Pharmacy Residency certificate and a PGY2 Investigational Drugs and Research Residency certificate.

Residency Sites


The Ohio State University Wexner Medical Center (OSUWMC) is a 1,506 bed tertiary care medical center located in Columbus, Ohio. It is a multi-hospital delivery system recognized in 2022 as one of “America’s Best Hospitals” for excellence in 9 specialties by US News and World Report based on quality, outcomes, and reputation.

Read More

The James Cancer Hospital and Solove Research Institute

The OSUCCC – James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care — a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.

University Hospital (UH)

University Hospital (UH) will serve as an additional site serving patients and research in non-oncologic disease states.  UH is our flagship hospital with over 900 beds and is a major referral center for patients throughout Ohio and the Midwest, and is one of the busiest kidney and pancreas transplant centers in the world. UH is also an international center for neuromodulation research and neurological care. In addition, UH is a level 1 trauma center in addition to being the American Burn Associated verified adult burn center for the region.

Key Rotations / Experiences


Rotational experience is designed to provide the resident with broad exposure to pharmacy services and patient populations and is the backbone of the PGY1 Residency experience. The structure of the resident’s rotation schedule will be tailored to each resident.

Please see additional information:


The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.  The following is a list of the required learning experiences:

  • Orientation
  • Investigational Drug Service (IDS) Core
  • IDS Leadership
  • Clinical Trial Office
  • Clinical Trial Management Office
  • Office of Responsible Research Practices
  • Clinical Inpatient
  • Clinical Outpatient
  • Clinical Treatment Unit
  • Research Informatics
  • Drug Development Institute
  • Precepting
  • Teaching
  • Institutional Review Board
  • IDS Longitudinal
  • Clinical or Quality Research Project
  • Operational Staffing

Elective offerings may vary according to the interests of the resident.

Key Preceptors

Hallie Barr, PharmD, MBA, BCOP
Pharmacy Manager, Investigational Drug Service

Kelley Barley, PharmD
Research Pharmacist

Naomi Digiantonio, PharmD, BCPS
Generalist Pharmacist, Clinical Treatment Unit

Emily Harmon, PharmD
Research Pharmacist

Daniel Haas, MS, RPh
Research Pharmacist

Amanda Sabol, PharmD, MPH, BCPS
Research Pharmacist

Jennifer Severing, PharmD, BCPS
Research Pharmacist

Alexis Mann, PharmD, MBA
Research Pharmacist

Jeffrey Patrick, PharmD
Director, Drug Development Institute

Sandra Meadows, MPH, CIP
Program Manager, Educational Programming and Regulatory Support
Office of Responsible Research Practices

Kristina Humphries
Assistant Director, Clinical Trials Office
OSU Comprehensive Cancer Center

Lisa Hafer, MPH, CCRP
Assistant Director-Operations, Clinical Trials Management Organization
Center or Clinical Research Management, College of Medicine

Benefits and Additional Requirements

Application Deadline:  January 2, 2024

We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).

Along with your application, we require three letters of recommendation. It is highly recommended that one to two of the letters be from a clinical rotation preceptor within the past six months.

Start Date: June 17, 2024

Annual Salary- PGY1 $53,000/PGY2 $54,000

Vacation Days- 10 days per year

Staffing Requirement- PGY1 = 24 weekends; PGY2 = 20 weekends

Completion of a Major Research Project in each year


Download PDF